Privium Fund Acquires $5.07 Million Stake in Denali Therapeutics Ahead of FDA Drug Approval
On May 5, 2026, Privium Fund Management B.V. disclosed a new position in Denali Therapeutics (DNLI), acquiring approximately 254,857 shares valued at $5.07 million based on quarterly average pricing. The quarter-end value of the stake was reported as $4.89 million due to price fluctuations.
Tickers: $AMZN $DNLI $PLTR $SHOP $SPOT $TSLA
Topics: 13F filings Denali Therapeutics investment funds stock purchases